The role of tau phosphorylation and cleavage in neuronal cell death
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
The microtubule-associated protein tau is the primary component of the intracellular filamentous deposits found in Alzheimer's disease (AD) brain and also in a family of neurodegenerative diseases called 'tauopathies', where tau pathology is the primary, defining characteristic with little or no amyloid-beta (Abeta) pathology. It has been demonstrated that tau modifications such as hyperphosphorylation and truncation might be important events in the process leading to tau intracellular aggregation and neuronal cell death. The discovery of tau gene mutations in frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) reinforced the predominant role attributed to tau proteins in the pathogenesis of neurodegenerative disorders. This review highlights recent findings concerning the normal metabolism and function of tau, as well as the abnormal processing and function of tau in AD and in the tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“A dysfunction of the UPS has been proposed in numerous neurological disorders such as AD, Huntington’s disease, Parkinson’s disease, and Angelman’s syndrome (254-259).”
BackgroundGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 12×
“Although the role of NFTs as a toxic mediator in neuronal dysfunction and death in AD is still not clear, the tau aggregation is closely related with the pathology of AD (203), and there is increasing data to suggest that a conformational change in tau that precedes the formation of PHFs and NFTs may be the toxic enti…”
BackgroundInfluentialGSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 18×
“However, GSK3beta phosphorylates and regulates numerous other proteins (131), and therefore the possibility remains that GSK3beta indirectly regulates tau phosphorylation in vivo.”
InfluentialCaughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · cited 2×
“Although the role of NFTs as a toxic mediator in neuronal dysfunction and death in AD is still not clear, the tau aggregation is closely related with the pathology of AD (203), and there is increasing data to suggest that a conformational change in tau that precedes the formation of PHFs and NFTs may be the toxic enti…”
BackgroundA multiubiquitin chain is confined to specific lysine in a targeted short-lived protein
Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K., & Varshavsky, A. (1989) · Science · doi:10.1126/science.2538923 · Cited by 1,535 · cited 1×
“In addition, most PHFtau is mono-ubiquitylated (247), which is not a signal for ubiquitin-mediated degradation (249, 250).”
BackgroundMutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474 · cited 3×
“These diseases include the FTDP-17 cases, which are caused by mutations in the tau gene (11-13).”
BackgroundA68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“Although tau in AD and other tauopathies is present predominantly as an intact full-length molecule (212-216), tau in AD NFTs has been shown to be truncated both at Glu391 and Asp421 (47, 217).”
Background
Cited by
Recent aspects of the effects of zinc on human health
Chasapis, C. T., Ntoupa, P.-S. A., Spiliopoulou, C. A., & Stefanidou, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02702-9 · Cited by 702
How does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492
The importance of tau phosphorylation for neurodegenerative diseases
Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475
“Phosphorylation of tau by GSK-3 promotes the formation of insoluble oligomeric tau species that can constitute both full-length and truncated tau species (62, 63).”
BackgroundStructure and Pathology of Tau Protein in Alzheimer Disease
Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., & Ripova, D. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/731526 · Cited by 468
Ghosh, S., Wu, M. D., Shaftel, S. S., Kyrkanides, S., LaFerla, F. M., Olschowka, J. A., & O'Banion, M. K. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4361-12.2013 · Cited by 390
“Both GSK3 and p38MAPK have been studied for their ability to phosphorylate tau ( Chun and Johnson , 2007 ) .”
BackgroundAcetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection
Singh, M., Kaur, M., Kukreja, H., Chugh, R., Silakari, O., & Singh, D. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.050 · Cited by 364
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“…neurotoxicity of early aggregated state (before fibril formation and after hyperphosphorylation), contributing to disruption of neuronal circuits due to synapse loss and eventual cell death (Chun and Johnson 2007; Mondragon-Rodriguez et al. 2009; Spires-Jones et al. 2009; Takashima 2008).”
BackgroundTargeting the neural extracellular matrix in neurological disorders
Soleman, S., Filippov, M. A., Dityatev, A., & Fawcett, J. W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.050 · Cited by 244
Luna-Muñoz, J., Chávez-Macías, L., García-Sierra, F., & Mena, R. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12410 · Cited by 233
Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress
Manolopoulos, K. N., Klotz, L.-O., Korsten, P., Bornstein, S. R., & Barthel, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.17 · Cited by 150
Rohn, T. T., Vyas, V., Hernandez-Estrada, T., Nichol, K. E., Christie, L.-A., & Head, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5620-07.2008 · Cited by 146
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
“Of more importance, the hyperphosphorylation of tau protein causes the collapse of microtubules, leads to a cascade disintegration, and eventually destroys the fundamental structure of the neuron’s transport system, which end ups with neuronal cell death [64,65].”
BackgroundThe Proteasome and Oxidative Stress in Alzheimer's Disease
Bonet-Costa, V., Pomatto, L. C.-D., & Davies, K. J. A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6802 · Cited by 99
“This is seen through the accumulation of ubiquitin in amyloid deposits and NFTs. Additionally, a mutant form of ubiquitin has been observed in the brains of Alzheimer’s patients.”
InfluentialSotiropoulos, I., Catania, C., Riedemann, T., Fry, J. P., Breen, K. C., Michaelidis, T. M., & Almeida, O. F. X. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05613.x · Cited by 97
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
“This results in the disintegration of the microtubule and the destruction of neuronal transport [48], leading to impaired communication between neurons and, finally, their death [49].”
BackgroundThe toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
ECM in brain aging and dementia
Morawski, M., Filippov, M., Tzinia, A., Tsilibary, E., & Vargova, L. (2014) · Progress in Brain Research · doi:10.1016/b978-0-444-63486-3.00010-4 · Cited by 84
Metadata
- Authors
- Chun, W.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2007
- Volume
- 12
- Issue
- 1
- Pages
- 733
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/2097
- OpenAlex
- W2050562362
- Cited by
- 142
- References
- 73
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.